RCL Surges After Earnings as Analysts Race to Raise Targets

Royal Caribbean delivered a strong Q3 earnings print on October 27, and the market's reaction was immediate: the stock jumped 5.5% on the day to close at $295.92, adding to a 22% gain over the past month and capping a week in which the shares rose nearly 3%.

The analyst community moved quickly to reflect the results. Barclays raised its price target to $350 from $337 while holding its Overweight rating. Wells Fargo nudged its target to $361 from $358, also keeping Overweight. Susquehanna lifted to $360 from $355. All three moves came within hours of the earnings release on October 28, and all three kept positive ratings in place. The Street consensus price target now sits at $352, implying roughly 19% upside from the current price. That analyst recommendation score ranks in the 100th percentile of the ORTEX universe, meaning virtually no coverage has a negative view on the stock. EPS surprise ranks in the 70th percentile, and EPS momentum over the past 30 and 90 days registers in the low-to-mid 60s, consistent with a business that keeps nudging estimates higher.

Short interest, by contrast, tells a quieter story. The month-long accumulation of shorts documented in the pre-earnings note has begun to reverse. Short interest dipped 5.4% over the past week to 4.5% of free float, down from a peak above 13 million shares in mid-October to roughly 12.2 million now. The post-earnings unwind makes sense: a considered bearish position heading into the print has had its thesis tested and found wanting. The borrow market confirms there is no squeeze mechanics at work here. Availability remains extraordinarily loose at 1,530%, meaning more than 15 shares are available to borrow for every one already lent out, far above even the 52-week tightest reading of around 792%. Borrowing costs hold at 0.51%, barely above zero. The ORTEX short score has drifted down to 43.6 from 45 two weeks ago, consistent with reducing short pressure.

Options positioning has edged more defensive in the run-up to and through the print. The put/call ratio is 1.06, above its 20-day average of 0.96 and running about 1.2 standard deviations above that mean. That is elevated but not extreme: the 52-week high on the PCR is 2.08, so there is considerable headroom before this reads as a genuine crowded hedge. The direction of travel in the PCR since early October is the more informative signal, with the ratio climbing steadily from below 0.85 in late September to its current level. Some of that hedging demand was likely the market pricing tail risk into the earnings event itself.

One ownership detail is worth noting. Capital Research Global Investors filed a 13G amendment on October 6, disclosing a 6.4% stake, down from 12.8% at the prior filing. The broader Capital Research and Management entity remains the largest holder at 29.4% of shares, so this appears to reflect internal restructuring within the Capital Group complex rather than a meaningful reduction in a long-term owner's conviction. No 13D activist is on the register. As always with 13D/G disclosures, stakes are as last reported around the 5% threshold, and positions can change without a further filing.

An alt data point adds colour to the post-earnings picture. Royal Caribbean reported the largest Q2 buyback spend on record, at $199 million, according to SEC EDGAR XBRL filings tracked by ORTEX. Wikipedia page views also spiked sharply in late September, with a retail attention z-score of 3.26 against the stock's own 90-day history, a signal of elevated public interest that preceded the earnings catalyst. Neither dataset has been measured as a leading indicator of the company's reported financial figures, so they describe context rather than preview the next print.

The next earnings event is scheduled for January 28, 2027, leaving 92 days for the market to decide whether the current valuation, a P/E of roughly 14.8 and EV/EBITDA near 12, adequately captures the company's forward growth profile. What to watch in the weeks ahead: whether shorts continue to cover after the earnings unwind, and whether the PCR normalises back toward its 20-day mean now that the event risk has passed.